9IB Stock Chart & Stats
€4.48
-€0.15(-3.23%)
At close: 4:00 PM EST
€4.48
-€0.15(-3.23%)
Day’s Range― - ―
52-Week Range€3.91 - €7.53
Previous CloseN/A
Volume0.00
Average Volume (3M)34.00
Market Cap
€80.38M
Enterprise Value€834.40M
Total Cash (Recent Filing)€108.60M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Nov 13, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.09
Shares Outstanding13,018,137
10 Day Avg. Volume70
30 Day Avg. Volume34
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)6.46
Price to Sales (P/S)0.00
P/FCF Ratio-9.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of debt reduces interest obligations and refinancing exposure while the company funds clinical development. This provides greater financial flexibility than a leveraged biotech, although it does not remove the need for future financing while programs remain pre-commercial.
Moderating Cash BurnThe reduction in negative operating and free cash flow suggests some spending moderation as development continues. If maintained, lower burn could extend financial flexibility and make future funding more efficient, even though the company has not yet reached cash generation.
Focused Infant Microbiome PlatformA focused platform addressing serious conditions in preterm infants can support specialized clinical expertise and a differentiated product position if efficacy is demonstrated. The lead program’s defined medical objective gives development efforts a coherent strategic direction.
Bears Say
No Commercial RevenueThe absence of product revenue confirms that the business has not yet reached commercialization and has no established recurring sales base. Future economic value therefore depends on successful clinical development, regulatory approval, and eventual commercialization or partnering.
Persistent Operating LossesLarge continuing losses show that operating expenses and development spending substantially exceed current income. This weak earnings profile can persist until a candidate is commercialized or partnered, limiting internal reinvestment capacity and increasing dependence on strategic execution.
Equity Erosion And Funding DependenceMaterial equity erosion reflects the cumulative effect of losses and cash consumption, reducing the financial base available to support development. Continued reliance on external funding may create dilution pressure and constrain the company’s ability to finance programs independently.
Infant Bacterial Therapeutics AB News
9IB FAQ
What was Infant Bacterial Therapeutics AB’s price range in the past 12 months?
Infant Bacterial Therapeutics AB lowest stock price was €3.91 and its highest was €7.53 in the past 12 months.
What is Infant Bacterial Therapeutics AB’s market cap?
Infant Bacterial Therapeutics AB’s market cap is €80.38M.
When is Infant Bacterial Therapeutics AB’s upcoming earnings report date?
Infant Bacterial Therapeutics AB’s upcoming earnings report date is Nov 13, 2026 which is in 12 days.
How were Infant Bacterial Therapeutics AB’s earnings last quarter?
Infant Bacterial Therapeutics AB released its earnings results on Aug 26, 2026. The company reported -€0.201 earnings per share for the quarter, missing the consensus estimate of -€0.142 by -€0.059.
Is Infant Bacterial Therapeutics AB overvalued?
According to Wall Street analysts Infant Bacterial Therapeutics AB’s price is currently Overvalued.
Does Infant Bacterial Therapeutics AB pay dividends?
Infant Bacterial Therapeutics AB does not currently pay dividends.
What is Infant Bacterial Therapeutics AB’s EPS estimate?
Infant Bacterial Therapeutics AB’s EPS estimate is -0.24.
How many shares outstanding does Infant Bacterial Therapeutics AB have?
Infant Bacterial Therapeutics AB has 13,018,137 shares outstanding.
What happened to Infant Bacterial Therapeutics AB’s price movement after its last earnings report?
Infant Bacterial Therapeutics AB reported an EPS of -€0.201 in its last earnings report, missing expectations of -€0.142. Following the earnings report the stock price went up 2.838%.
Which hedge fund is a major shareholder of Infant Bacterial Therapeutics AB?
Currently, no hedge funds are holding shares in DE:9IB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Xbrane Biopharma AB
―
Intervacc AB
―
ExpreS2ion Biotech Holding AB
―